{
    "id": 32609,
    "fullName": "SIRT6 dec exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "SIRT6 dec exp indicates decreased expression of the Sirt6 protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 51548,
        "geneSymbol": "SIRT6",
        "terms": [
            "SIRT6",
            "SIR2L6"
        ]
    },
    "variant": "dec exp",
    "createDate": "02/18/2020",
    "updateDate": "02/18/2020",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 20485,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreased Sirt6 expression through siRNA knockdown resulted in activation of IGF-1R/AKT pathway, conferred resistance to Tafinlar (dabrafenib) in melanoma cell lines and patient-derived melanoma cells harboring BRAF V600E in culture (PMID: 30143629).",
            "molecularProfile": {
                "id": 35191,
                "profileName": "BRAF V600E SIRT6 dec exp"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17876,
                    "pubMedId": 30143629,
                    "title": "SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30143629"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20490,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreased Sirt6 expression was identified in cells derived from patients with melanoma harboring BRAF V600E at times of disease progression while on Zelboraf (vemurafenib), and melanoma cell lines harboring BRAF V600E and with decreased Sirt6 expression through siRNA knockdown were resistance to Zelboraf (vemurafenib) in cell line xenograft models (PMID: 30143629).",
            "molecularProfile": {
                "id": 35191,
                "profileName": "BRAF V600E SIRT6 dec exp"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17876,
                    "pubMedId": 30143629,
                    "title": "SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30143629"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20493,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of Tafinlar (dabrafenib) and Linsitinib (OSI-906) enhanced inhibition of Igf1r and Akt phosphorylation, led to apoptosis and reduced proliferation in BRAF V600E melanoma cells with decreased Sirt6 expression via siRNA knockdown in culture, and tumor regression in cell line xenograft models (PMID: 30143629).",
            "molecularProfile": {
                "id": 35191,
                "profileName": "BRAF V600E SIRT6 dec exp"
            },
            "therapy": {
                "id": 9382,
                "therapyName": "Dabrafenib + Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17876,
                    "pubMedId": 30143629,
                    "title": "SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30143629"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20486,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreased Sirt6 expression through siRNA knockdown resulted in activation of IGF-1R/AKT pathway, conferred resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in melanoma cell lines and patient-derived melanoma cells harboring BRAF V600E in culture (PMID: 30143629).",
            "molecularProfile": {
                "id": 35191,
                "profileName": "BRAF V600E SIRT6 dec exp"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17876,
                    "pubMedId": 30143629,
                    "title": "SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30143629"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 35190,
            "profileName": "SIRT6 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35191,
            "profileName": "BRAF V600E SIRT6 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}